GlassScriptPhysician profile
Swetha Rao Arshanapally
NPI 1720222094
$3,379.02
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,577 · 2020: $727 · 2024: $74.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $369.88 | 2019-2020 | |
| Pfizer INC. | $304.32 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $293.13 | 2019-2020 | |
| Janssen Biotech, INC. | $286.79 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $253.90 | 2019-2020 | |
| Lilly USA, LLC | $170.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $155.79 | 2019-2020 | |
| Incyte Corporation | $119.40 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $110.56 | 2019 | |
| Merck Sharp & Dohme LLC | $100.65 | 2019-2020 | |
| Kite Pharma, INC. | $96.45 | 2019 | |
| Daiichi Sankyo INC. | $84.44 | 2019-2020 | |
| Genzyme Corporation | $74.42 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $70.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.05 | 2019-2020 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $69.50 | 2019 | |
| Kyowa Kirin, INC. | $69.34 | 2019-2020 | |
| Amgen INC. | $64.95 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.78 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $58.69 | 2019 | |
| Secura Bio, INC. | $54.53 | 2019-2020 | |
| Celgene Corporation | $48.65 | 2019 | |
| Gilead Sciences, INC. | $35.96 | 2019 | |
| Taiho Oncology, INC. | $35.17 | 2019 | |
| Astellas Pharma US INC | $33.75 | 2019-2020 | |
| Tersera Therapeutics LLC | $30.88 | 2019 | |
| Janssen Scientific Affairs, LLC | $24.77 | 2019 | |
| Seagen INC. | $18.11 | 2019 | |
| Sun Pharmaceutical Industries INC. | $17.87 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $17.41 | 2019 | |
| Mylan Institutional INC. | $17.26 | 2019 | |
| Abbvie INC. | $17.16 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $16.49 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.49 | 2019 | |
| Dova Pharmaceuticals | $16.39 | 2020 | |
| Array Biopharma INC | $16.29 | 2020 | |
| Karyopharm Therapeutics INC. | $16.25 | 2020 | |
| Glaxosmithkline, LLC. | $15.94 | 2020 | |
| Emd Serono, INC. | $15.93 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.43 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swetha Arshanapally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.